EXACT Sciences (NASDAQ:EXAS) has been assigned a $67.00 price objective by equities researchers at Bank of America in a research report issued to clients and investors on Monday. The brokerage presently has a “buy” rating on the medical research company’s stock. Bank of America’s price objective would indicate a potential upside of 16.46% from the company’s current price.

Other research analysts have also issued reports about the stock. Jefferies Group upped their target price on shares of EXACT Sciences to $60.00 and gave the company a “buy” rating in a report on Tuesday, October 31st. Robert W. Baird restated a “buy” rating and issued a $49.00 target price on shares of EXACT Sciences in a report on Friday, October 6th. Canaccord Genuity reiterated a “buy” rating and set a $60.00 price objective (up from $45.00) on shares of EXACT Sciences in a report on Tuesday, October 3rd. Zacks Investment Research upgraded shares of EXACT Sciences from a “hold” rating to a “buy” rating and set a $51.00 price objective on the stock in a report on Tuesday, September 26th. Finally, Craig Hallum increased their price objective on shares of EXACT Sciences from $46.00 to $61.00 and gave the stock a “buy” rating in a report on Tuesday, October 31st. Eight investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $50.58.

EXACT Sciences (NASDAQ EXAS) opened at $57.53 on Monday. The stock has a market cap of $6,888.09, a PE ratio of -49.59 and a beta of 0.68. The company has a quick ratio of 9.98, a current ratio of 10.34 and a debt-to-equity ratio of 0.01. EXACT Sciences has a 1-year low of $14.93 and a 1-year high of $63.60.

EXACT Sciences (NASDAQ:EXAS) last released its earnings results on Monday, October 30th. The medical research company reported ($0.23) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.30) by $0.07. The company had revenue of $72.60 million for the quarter, compared to analyst estimates of $65.03 million. EXACT Sciences had a negative net margin of 60.71% and a negative return on equity of 30.32%. The firm’s quarterly revenue was up 158.4% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.36) EPS. equities research analysts predict that EXACT Sciences will post -1.1 earnings per share for the current year.

In related news, insider Kevin T. Conroy sold 123,512 shares of the stock in a transaction that occurred on Friday, December 22nd. The shares were sold at an average price of $52.58, for a total transaction of $6,494,260.96. Following the completion of the sale, the insider now owns 953,564 shares of the company’s stock, valued at approximately $50,138,395.12. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP D Scott Coward sold 1,665 shares of the stock in a transaction that occurred on Wednesday, January 3rd. The stock was sold at an average price of $52.54, for a total transaction of $87,479.10. Following the sale, the senior vice president now directly owns 37,558 shares of the company’s stock, valued at approximately $1,973,297.32. The disclosure for this sale can be found here. In the last three months, insiders have sold 610,433 shares of company stock valued at $34,341,306. Corporate insiders own 4.00% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Krilogy Financial LLC increased its position in EXACT Sciences by 1,460.0% during the 2nd quarter. Krilogy Financial LLC now owns 3,900 shares of the medical research company’s stock worth $138,000 after purchasing an additional 3,650 shares in the last quarter. Northwestern Mutual Wealth Management Co. grew its position in EXACT Sciences by 17.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 4,072 shares of the medical research company’s stock valued at $144,000 after acquiring an additional 600 shares in the last quarter. Oppenheimer Asset Management Inc. grew its position in EXACT Sciences by 2,925.7% in the third quarter. Oppenheimer Asset Management Inc. now owns 3,177 shares of the medical research company’s stock valued at $150,000 after acquiring an additional 3,072 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in EXACT Sciences by 66.2% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,052 shares of the medical research company’s stock valued at $179,000 after acquiring an additional 2,013 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new stake in EXACT Sciences in the third quarter valued at approximately $183,000. 82.39% of the stock is owned by hedge funds and other institutional investors.

WARNING: This article was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another site, it was illegally copied and reposted in violation of US and international copyright legislation. The correct version of this article can be read at https://www.thecerbatgem.com/2018/01/08/exact-sciences-exas-earns-buy-rating-from-bank-of-america.html.

About EXACT Sciences

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Analyst Recommendations for EXACT Sciences (NASDAQ:EXAS)

Receive News & Stock Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related stocks with our FREE daily email newsletter.